Drug Profile

NUV 1511

Alternative Names: NUV-1511

Latest Information Update: 22 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nuvation Bio
Class Antineoplastics; Drug conjugates
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

14 Mar 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in the US (IV) (NCT06334432)
08 Jan 2024 Nuvation Bio plans a phase I/II trial for HER2-positive-breast-cancer (Metastatic disease), Ovarian cancer, Pancreatic cancer, Prostate cancer, Solid tumours (Late-stage disease, Second-line therapy and greater) in the first half of 2024
08 Jan 2024 Preclinical trials in Solid tumours in USA (unspecified route) prior to January 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com